Patents Examined by G. R. Ewoldt
  • Patent number: 10934354
    Abstract: Combinations of anti-cancer antibodies and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: March 2, 2021
    Assignees: The Johns Hopkins University, St. Jude's Children's Research Hospital, Inc.
    Inventors: Drew M. Pardoll, Ching-Tai Huang, Jonathan Powell, Charles G. Drake, Dario A. Vignali, Creg J. Workman
  • Patent number: 10925933
    Abstract: The present disclosure relates to a method of preventing rheumatoid arthritis comprising administering a polynucleotide encoding Ssu72.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: February 23, 2021
    Assignee: CUROGEN TECHNOLOGY CO., LTD.
    Inventors: Mi-La Cho, Sung-Hwan Park, Seung-Ki Kwok, Jong-Young Choi, Seung-Hun Lee, Hyeon-Beom Seo, Young-Mee Moon, Jin-Sil Park, Min-Jung Park, Jin-Kwan Lee, Chang Woo Lee
  • Patent number: 10899795
    Abstract: The present invention relates to immunogenic peptides comprising a T-cell epitope. Said peptides are modified such that CD4+ T-cell responses are obtainable that are much stronger than the CD4+ T-cell responses obtained with the same peptides not comprising said modification. In particular, the modification is the addition of a cysteine, insertion of a cysteine or mutation into a cysteine of a residue at a position adjacent to but outside the MHC-binding site of the peptide. Further disclosed are the use of such modified peptides in treating, suppressing or preventing diseases such as infectious or allergic diseases and autoimmune diseases, in preventing or suppressing graft rejection, or in the eradication of tumor cells.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: January 26, 2021
    Assignees: LIFE SCIENCES RESEARCH PARTNERS VZW, KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 10877033
    Abstract: The invention relates to methods of detecting the presence or absence of autoantibodies in an individual and to related methods and kits. In particular, the disclosure concerns measuring from one or more samples from an individual suspected of having a disease with an autoimmune component for binding of one or more autoantibodies to membrane vesicles comprising corresponding one or more antigens.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: December 29, 2020
    Assignee: Oxford University Innovation Limited
    Inventors: Angela Vincent, Patrick Joseph Waters, Alexandru Radu Aricescu
  • Patent number: 10864232
    Abstract: The present invention provides modified natural killer T (NKT) cells, pharmaceutical compositions comprising the modified NKT cells and at least one pharmaceutically acceptable carrier or excipient, and uses of the modified NKT cells. Also disclosed herein are methods for enriching NKT cells and generating the modified natural killer T cells.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: December 15, 2020
    Assignee: FULLHOPE BIOMEDICAL CO., LTD.
    Inventors: Jan-Mou Lee, Chih-Hao Fang, Ya-Fang Cheng, Da-Tsen Wei, Kai-Yuan Jhou
  • Patent number: 10857219
    Abstract: Compositions that include one isolated, class I HLA-E trimolecular complex that includes a peptide ligand unique to M. tuberculosis-infected cells are disclosed. Isolated compositions that include the three components of the trimolecular complex and/or a polynucleotide encoding one or more of the three components are also disclosed.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: December 8, 2020
    Assignees: The Board of Regents of the University of Oklahoma, Oregon Health & Science University, The United States Government as Represented by the Department of Veterans Affairs
    Inventors: William H. Hildebrand, Curtis McMurtrey, David Lewinsohn, Deborah Lewinsohn, Melanie Harriff
  • Patent number: 10851148
    Abstract: MICA and MICB are expressed on the surface of stressed, virus infected and cancer cells; they bind to their common receptor NKG2D on immune effector cells such as natural killer (NK) cells and some T cells to signal immune responses, including cytotoxicity, towards cells expressing surface MICA or MICB. To evade this immune-surveillance, virus infected cells and cancer cells shed the extracellular domain of their MICA and MICB as soluble forms (sMICA and sMICB) which act as decoys by binding and down-regulating expression of NKG2D on the immune effector cells. Antibodies are provided that specifically bind the soluble forms of both MICA and MICB to inhibit their adverse effects, but do not bind cell- or membrane-bound MICA and MICB to preserve their beneficial immune effects.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: December 1, 2020
    Assignee: Novelogics Biotechnology, Inc.
    Inventor: Ian Wayne Cheney
  • Patent number: 10844118
    Abstract: The methods, compositions, and assays described herein are based, in part, on the discovery that CD1a mediates inflammation related to certain conditions such as urushiol exposure, psoriasis and other inflammatory skin diseases. One aspect provided herein relates to a method for treating or preventing an inflammatory skin disease, the method comprising: administering a therapeutically effective amount of an inhibitor of CD 1a to a subject having an inflammatory skin disease, thereby treating or preventing the inflammatory skin diseases.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: November 24, 2020
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Florian E. Winau, Ji Hyung Kim
  • Patent number: 10829526
    Abstract: Methods of treating autoimmune diseases, such as vitiligo, by using compositions comprising DNA encoding a variant inducible heat shock protein 70 (HSP70i) having a mutation in the dendritic cell binding region thereof (HSP70i435-447) or an isolated variant gene product in the form of HSP70i with a modification in the dendritic cell activating region thereof (HSP70i435-447).
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: November 10, 2020
    Assignee: LOYOLA UNIVERSITY OF CHICAGO
    Inventors: I. Caroline Le Poole, Jose Alejandro Guevara, Andrew Zloza
  • Patent number: 10813952
    Abstract: Disclosed herein are modified NK cells, compositions comprising modified NK cells, and methods for treating a tumor or hyperproliferative disease in a subject. In some embodiments, the modified NK cells include NK cells including a heterologous nucleic acid molecule encoding a CD16 protein comprising a valine at amino acid position 158 (CD16-V158), a heterologous nucleic acid molecule encoding a CCR7 protein, or both. In some embodiments, methods include treating a subject with a tumor by administering a composition comprising an anti-cancer monoclonal antibody and administering a composition comprising the modified NK cells to the subject. Also disclosed are methods of making modified NK cells by obtaining a population of NK cells from a subject and transfecting the population of NK cells with a heterologous nucleic acid molecule encoding CD16-V158, a heterologous nucleic acid molecule encoding a CCR7 protein, or both.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: October 27, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Richard W. Childs, Mattias C.V. Carlsten
  • Patent number: 10813950
    Abstract: The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the ?-chain region of the T cell receptor gene rearranged to uniform V?-J? in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the ?-chain region of a T cell receptor (TCR) gene has been rearranged to uniform V?-J?. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: October 27, 2020
    Assignee: RIKEN
    Inventors: Masaru Taniguchi, Haruhiko Koseki, Hiroshi Watarai, Shin-ichiro Fujii
  • Patent number: 10800847
    Abstract: Provided herein are compositions comprising anti-HLA-Ib antibodies (monoclonal, mixed monoclonal, recombinant, chimeric, humanized or human antibodies) as IVIg mimetics and methods for using the same for the prevention, treatment, therapy and/or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-HLA-Ib antibodies strongly mimic IVIg in immunoreactivity to HLA class Ia (HLA-A, HLA-B and HLA-Cw) and Ib antigens (HLA-E, HLA-F and HLA-G). In certain embodiments, the anti-HLA-Ib antibodies strongly mimic IVIg in immunomodulatory or immunosuppressive activities. Methods are also provided herein to induce production of polyclonal anti-HLA-Ib antibodies in cancer patients for restoring anti-tumor activities of CD8+ T cells and NK cells, by active specific immunotherapy.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: October 13, 2020
    Inventors: Mepur H. Ravindranath, Paul I. Terasaki
  • Patent number: 10793633
    Abstract: The present disclosure provides, in part, compositions comprising peptides that immunospecifically bind to a defined binding partner, such as MHC class I polypeptide-related sequence A (MICA), or an epitope thereon. In some embodiments, the peptides comprise one or more complementarity determining regions relating to the complementarity regions shown in Table 1. The disclosure also provides methods of treating cancer in a subject using the compositions disclosed herein, and methods of isolating human antibodies from cancer patients following immunotherapy.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: October 6, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Kai W. Wucherpfennig, Bettina Franz, Kenneth F. May, Jr., Glenn Dranoff, F. Stephen Hodi, Christopher Harvey
  • Patent number: 10792348
    Abstract: Materials and methods for identifying and using MEW molecule variants for activating self-reactive T cells in a peptide-specific manner, and their use to focus autoimmune cellular responses against diseases such as cancers and persisting viral infections, are described.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: October 6, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Larry R. Pease
  • Patent number: 10787513
    Abstract: Anti-CD223 antibodies overcome immune suppression in cancer patients. The anti-CD223 antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: September 29, 2020
    Assignees: The Johns Hopkins University, St. Jude's Children's Research Hospital, Inc.
    Inventors: Drew M. Pardoll, Ching-Tai Huang, Jonathan Powell, Charles Drake, Dario A. Vignali, Creg J. Workman
  • Patent number: 10774129
    Abstract: Novel complexes of peptides from human collagen type II and types of MHC class II associated with rheumatoid arthritis are provided. There is also provided novel therapies and methods for diagnosis of rheumatoid arthritis.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: September 15, 2020
    Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    Inventor: Rikard Holmdahl
  • Patent number: 10767167
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: September 8, 2020
    Assignees: INSTITUT PASTEUR, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut
  • Patent number: 10760054
    Abstract: The invention provides compositions and methods of culturing Natural Killer Cells that increase viability, proliferation and cytotoxicity following cryopreservation.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: September 1, 2020
    Assignee: RESTEM LLC
    Inventors: Nickolas Chelyapov, Rafael Gonzalez
  • Patent number: 10745483
    Abstract: The present disclosure provides, in part, compositions comprising peptides immuno specifically binds to defined binding partners, wherein the peptides comprise at least complementarity determining regions relating to the complementarity regions shown in Table 1.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 18, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, F. Stephen Hodi, Bettina Franz, Kenneth F. May, Jr., Christopher Harvey
  • Patent number: 10711047
    Abstract: Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: July 14, 2020
    Assignee: ONCOTHERAPY SCIENCE, INC.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura